Tysabri's US label updated for rate of PML risk
09 February 2010
Katie McQue
Please Login to read the full article.
09 February 2010
Katie McQue
katie.mcque@informa.com
The US label and patient medication guide of
Elan/
Biogen Idec's multiple sclerosis drug Tysabri (natalizumab) have been updated to quantify the risk of developing the rare and sometimes fatal brain infection, progressive multifocal leukoencephalopathy (PML), which increases with the number of drug...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Novartis's misfortunes with Gilenya could provide a boost for other MS drug makers
- FDA permits Biogen, Elan to add anti-JC virus status in Tysabri label
- US FDA delays decision on adding anti-JC virus status in Tysabri label
- Black-box warning imposed on Seattle Genetics' new lymphoma drug
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
